Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Medchemexpress LLC FTISADTSK-13C 6,15N2(TFA) | 1091.01 | 1 MG
Supplier: Medchemexpress LLC HYP3146S1MG
FTISADTSK-13C6,15N2 TFA is a 13C- and 15N-labeled derivative of FTISADTSK. It serves as an endogenous stable signature peptide from Trastuzumab, monitored by selected reaction monitoring (SRM). Stable heavy isotopes, such as carbon and nitrogen, are incorporated into drug molecules primarily as tracers for quantitation during drug development. This methodology, particularly deuteration, has shown potential in influencing the pharmacokinetic and metabolic profiles of drugs.
- 13C- and 15N-labeled compound.
- Endogenous stable signature peptide.
- Monitored by selected reaction monitoring (SRM).
- Useful as a tracer for quantitation in drug development.
- Incorporation of stable heavy isotopes can affect pharmacokinetic and metabolic profiles.
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?